IL2 and systemic lupus erythematosus: In addition, a single-center, uncontrolled study investigated clinical and immunological responses of a combination therapy with low-dose IL-2 applied monthly for 3-5 days and continuous treatment with rapamycin every other day in 50 patients with refractory SLE.